Literature DB >> 2400936

Comprehensive criteria for assessing therapy-induced toxicity.

J A Ajani1, S R Welch, M N Raber, W S Fields, I H Krakoff.   

Abstract

Methods of assessing and reporting toxic reactions induced by therapy, particularly chemotherapy, need improvements. Accurate and reliable reporting of therapy-induced toxicity will be necessary for quality clinical research including drug development and for implementation of complex multimodality treatments, currently, however, the extent and quality of reporting of toxic reactions vary widely. Whereas standard and widely accepted criteria have been established for assessing and reporting therapeutic response, no such criteria exist for toxicity. We have developed comprehensive criteria for assessing and reliably reporting toxic reactions. We have reduced the degree of subjectivity in assigning grades by using primarily objective methods. An attempt has been made to standardize the "morbidity impact" of each toxicity grade irrespective of the organ system involved.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2400936     DOI: 10.3109/07357909009017560

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  43 in total

1.  Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule.

Authors:  R Pazdur; Y Lassere; E Diaz-Canton; B Bready; D H Ho
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

2.  Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Authors:  Matthew G Fury; Shrujal Baxi; Ronglai Shen; Katherine W Kelly; Brynna L Lipson; Diane Carlson; Hilda Stambuk; Sofia Haque; David G Pfister
Journal:  Anticancer Res       Date:  2011-01       Impact factor: 2.480

3.  A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck.

Authors:  Carol M Lewis; Bonnie S Glisson; Lei Feng; Fiona Wan; Ximing Tang; Ignacio I Wistuba; Adel K El-Naggar; David I Rosenthal; Mark S Chambers; Robert A Lustig; Randal S Weber
Journal:  Clin Cancer Res       Date:  2012-01-18       Impact factor: 12.531

4.  Phase II study of tallysomycin S10b in patients with advanced colorectal cancer.

Authors:  C Nicaise; J Ajani; P Goudeau; M Rozencweig; B Levin; I Krakoff
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Phase I/II docetaxel plus concurrent hyperfractionated radiotherapy in locally advanced unresectable head and neck cancer (TAX.ES1.102 study).

Authors:  Agustí Barnadas; Ricard Mesía; Margarita Majem; Ramón Galiana; Antonio López-Pousa; José M de Vega; Mireia Margelí; Vicente Valentí; Lluís Anglada; Ariadna Lloansí; Antonio Arellano
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

6.  Phase I-II study of high-dose etoposide in patients with refractory breast cancer.

Authors:  G Fraschini; F A Holmes; L Esparza; R L Theriault; A U Buzdar; G N Hortobagyi
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

7.  Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation.

Authors:  Lise J Estcourt; Simon Stanworth; Carolyn Doree; Marialena Trivella; Sally Hopewell; Michael F Murphy; Alan Tinmouth
Journal:  Cochrane Database Syst Rev       Date:  2014

Review 8.  Docetaxel: an update of its use in advanced breast cancer.

Authors:  D P Figgitt; L R Wiseman
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

9.  Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study.

Authors:  Kathleen A Griffith; Susan G Dorsey; Cynthia L Renn; Shijun Zhu; Mary E Johantgen; David R Cornblath; Andreas A Argyriou; Guido Cavaletti; Ingemar S J Merkies; Paola Alberti; Tjeerd J Postma; Emanuela Rossi; Barbara Frigeni; Jordi Bruna; Roser Velasco; Haralabos P Kalofonos; Dimitri Psimaras; Damien Ricard; Andrea Pace; Edvina Galie; Chiara Briani; Chiara Dalla Torre; Catharina G Faber; Roy I Lalisang; Willem Boogerd; Dieta Brandsma; Susanne Koeppen; Joerg Hense; Dawn J Storey; Simon Kerrigan; Angelo Schenone; Sabrina Fabbri; Maria Grazia Valsecchi
Journal:  J Peripher Nerv Syst       Date:  2014-06       Impact factor: 3.494

10.  Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia.

Authors:  Sindhu Ramchandren; Marcia Leonard; Rajen J Mody; Janet E Donohue; Judith Moyer; Raymond Hutchinson; James G Gurney
Journal:  J Peripher Nerv Syst       Date:  2009-09       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.